Core Viewpoint - Medtronic is strategically appointing Chad Spooner as CFO of its diabetes division MiniMed to support the upcoming spin-off into an independent publicly traded company, aiming to establish a solid financial and strategic foundation for future growth [1][8]. Group 1: Appointment of Chad Spooner - Chad Spooner will officially take on the role of CFO for MiniMed starting July 14, 2025, coinciding with Medtronic's plans to spin off its diabetes business [1]. - Spooner brings over 25 years of financial leadership experience across various sectors, including healthcare and consumer goods, which will be crucial for MiniMed's transition to independence [6][9]. - His previous roles include CFO at BIC Group and co-founder of Tenex Capital Management, providing him with extensive experience in financial strategy and capital market operations [6][9]. Group 2: MiniMed's Spin-off Strategy - Medtronic announced plans to separate its diabetes business into an independent publicly traded company, expected to be completed within 18 months [3]. - MiniMed will focus on comprehensive insulin management systems, including automated insulin pumps and continuous glucose monitoring devices [3]. - The business model is shifting from traditional B2B to a direct-to-consumer (B2C) approach, emphasizing consumer experience and market responsiveness [9]. Group 3: Financial Implications and Market Response - Spooner's appointment is seen as a move to enhance investor confidence and improve market expectations regarding MiniMed's operational capabilities post-spin-off [10]. - Medtronic's fiscal year 2025 report indicated strong financial performance with total revenue of $33.537 billion and net income of $4.662 billion, which supports the rationale behind the spin-off [10]. - The stock price of Medtronic rose nearly 10% following the announcement of the spin-off, indicating positive market sentiment [10]. Group 4: Future Prospects and Innovations - MiniMed is at a critical stage of technological innovation, including collaborations on new continuous glucose monitoring systems and automated insulin delivery systems [9]. - Spooner's financial leadership is expected to provide necessary funding and resource allocation for high-potential projects, facilitating their transition from research and development to market [9]. - The strategic appointment of Spooner is anticipated to strengthen MiniMed's financial execution and market adaptability during this transformative phase [11].

Core Viewpoint - Midea Group plans to spin off its subsidiary, Ande Intelligent Supply Chain Technology Co., Ltd., for a listing on the main board of the Hong Kong Stock Exchange, which will not significantly change the company's equity structure and will maintain control over Ande Intelligent [1] Group 1 - The spin-off is expected to help Midea Group streamline its business management structure [1] - The move aims to unlock the valuation potential of the smart logistics segment [1] - The spin-off will provide Ande Intelligent with broader financing channels and improve its incentive mechanisms, enhancing the company's competitiveness [1]